Citations
Hereditary male breast cancer: genetic implications and therapeutic advances. A case report.
Cáncer de mama hereditario en hombres: implicaciones genéticas y avances terapéuticos. Un reporte de caso
Open | Download
How to Cite
1.
Manrique Moreno MA, Vargas Gómez J, Diaz JV, Alvarado Castell H, Hernández Lastra Ángel L. Hereditary male breast cancer: genetic implications and therapeutic advances. A case report. Rev. colomb. hematol. oncol. [Internet]. 2025 Nov. 30 [cited 2025 Dec. 5];12(2):56-63. https://doi.org/10.51643/22562915.765
Download Citation
Section
Clinic cases
How to Cite
1.
Manrique Moreno MA, Vargas Gómez J, Diaz JV, Alvarado Castell H, Hernández Lastra Ángel L. Hereditary male breast cancer: genetic implications and therapeutic advances. A case report. Rev. colomb. hematol. oncol. [Internet]. 2025 Nov. 30 [cited 2025 Dec. 5];12(2):56-63. https://doi.org/10.51643/22562915.765
Dimensions
license
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Show authors biography
Introduction: Male breast cancer accounts for approximately 1% of all breast cancer cases, with nearly 40% of cases associated with hereditary cancer, primarily linked to pathogenic variants in the BRCA1 and BRCA2 genes. These pathogenic variants significantly increase the risk of developing this malignancy, as well as other types of cancer. Clinical case: We present the case of a young male patient with a family history of breast cancer and a pathogenic BRCA2 variant, diagnosed with luminal A invasive ductal carcinoma, and treated with mastectomy and endocrine therapy with tamoxifen. Conclusion: Despite the low incidence of this disease, this case underscores the importance of precision medicine and targeted therapies in patients with hereditary breast cancer, as well as the need for genetic counseling for first-degree relatives to enable early detection and prevention of other malignancies.
Article visits 190 | PDF visits 16
Downloads
Download data is not yet available.
- Zheng G, Leone JP. Male breast cancer: An updated review of epidemiology, clinicopathology, and treatment. J Oncol. [Internet] 2022;2022:1–11. Disponible en: https://doi.org/10.1155/2022/1734049
- Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, et al. Genetic landscape of male breast cancer. Cancers (Basel). [Internet] 2021;13(14):3535. Disponible en: https://doi.org/10.3390/cancers13143535
- Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. [Internet] 2018;18(1):179. Disponible en: https://doi.org/10.1186/s12885-018-4098-y
- Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. [Internet] 2019:5(1):66. Disponible en: https://doi.org/10.1038/s41572-019-0111-2
- Khan NAJ, Tirona M. An updated review of epidemiology, risk factors, and management of male breast cancer. Med Oncol. [Internet] 2021;38(4):39. Disponible en: https://doi.org/10.1007/s12032-021-01486-x
- Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. [Internet] 2018;379(8):753–63. Disponible en: https://doi.org/10.1056/NEJMoa1802905
- Silvestri V, kConFab Investigators, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. [Internet] 2016;18(1):15. Disponible en: https://doi.org/10.1186/s13058-016-0671-y
- Kwong A, Ho CYS, Shin VY, Ng ATL, Chan TL, Ma ESK. Molecular characteristics of Asian male BRCA-related cancers. Breast Cancer Res Treat. [Internet] 2023;198(2):391–400. Disponible en: https://doi.org/10.1007/s10549-022-06651-y
- Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. [Internet] 2019;173(1):37–48. Disponible en: https://doi.org/10.1007/s10549-018-4921-9
- Bastos MCS, Almeida AP de, Bagnoli F, Oliveira VM de. Early breast cancer: concept and therapeutic review. Rev Assoc Med Bras. [Internet] 2023;69(suppl 1):e2023S114. Disponible en: https://doi.org/10.1590/1806-9282.2023S114
- Hassett MJ, Somerfield MR, Giordano SH. Management of male breast cancer: ASCO guideline summary. JCO Oncol Pract. [Internet] 2020;16(8):e839–43. Disponible en: https://doi.org/10.1200/JOP.19.00792
- Co M, Liu T, Leung J, Li CH, Tse T, Wong M, et al. Breast conserving surgery for BRCA mutation carriers-A systematic review. Clin Breast Cancer. [Internet] 2020;20(3):e244–50. Disponible en: https://doi.org/10.1016/j.clbc.2019.07.014
- Ye F, Huang L, Lang G, Hu X, Di G, Shao Z, et al. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation. Cancer Med. [Internet] 2020;9(5):1903–10. Disponible en: https://doi.org/10.1002/cam4.2836
- Eggemann H, Brucker C, Schrauder M, Thill M, Flock F, Reinisch M, et al. Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. Br J Cancer. [Internet] 2020;123(1):33–7. Disponible en: https://doi.org/10.1038/s41416-020-0857-z
- Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. [Internet] 2021;384(25):2394–405. Disponible en: https://doi.org/10.1056/NEJMoa2105215
- Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, et al. PARP inhibitors for breast cancer treatment: A review: A review. JAMA Oncol. 2024;10(5):658–70. Disponible en: https://doi.org/10.1001/jamaoncol.2023.7322
Tutorials
About the journal
Information
Directories and Indexers
Plagiarism Check
Descriptor
Google Scholar profile
QR code
Keywords
Most read in the last 30 days
